Regulators Launch Safety Reviews for Key Medications
Patients using Deanxit or human immunoglobulin should monitor for potential side effects and discuss concerns with a doctor.
Updated on Oct. 30, 2026 in Allergies
Live Poll
Do you trust pharmaceutical regulators to effectively manage the safety risks of common prescription medications?
The European Medicines Agency has launched safety reviews for the medication Deanxit and specific batches of human normal immunoglobulin. These investigations follow reports of potential neurological side effects and hypersensitivity reactions in patients.
Why it matters
Patients using these treatments may face risks of psychiatric symptoms or serious allergic reactions like anaphylaxis. These reviews aim to clarify the safety profiles of the products and determine necessary regulatory actions.
The Pharmacovigilance Risk Assessment Committee is conducting an active safety signal review based on reported adverse event clusters. While investigations are underway, the exact biological or manufacturing trigger for these reactions is still being determined.
The players
Pharmacovigilance Risk Assessment Committee
An European Medicines Agency body responsible for evaluating the safety of human medicines.
European Medicines Agency
The agency responsible for the scientific evaluation, supervision, and safety monitoring of medicines within the European Union.
The details
The review of Deanxit focuses on reports of movement disorders, memory impairment, and cognitive changes. Simultaneously, the committee is analyzing human normal immunoglobulin products, specifically investigating why certain batches have been associated with increased rates of anaphylaxis and angioedema. Regulators are currently gathering comprehensive data from pharmaceutical manufacturers to assess whether these issues stem from specific production processes or broader medication profiles.
Timeline
October 26-29, 2026: The Pharmacovigilance Risk Assessment Committee met to initiate these safety reviews.
Health Landscape
These investigations represent the standard safety monitoring protocols established by the EU Pharmacovigilance legislation. They reflect a broader clinical effort to continuously reassess the risk-benefit profiles of long-standing psychiatric and immune-modulating treatments.
Patients currently taking Deanxit or receiving human normal immunoglobulin should monitor for any new neurological symptoms or signs of allergic reactions. If you have concerns about your treatment, schedule a conversation with your physician to discuss these developments.
The takeaway
Ongoing safety reviews are evaluating serious reports related to specific medications and immune-based therapies. If you experience unexpected cognitive changes or allergic symptoms, contact your healthcare provider immediately to discuss your care plan.
Further reading
For context on how hypersensitivity is managed in clinical settings, visit Allergies.
Source note: This article includes information reported by European Medicines Agency (EMA).
Live Poll
Do you trust pharmaceutical regulators to effectively manage the safety risks of common prescription medications?
